JING JING PHARMACEUTICAL CO LTD, an exporting supplier of pharmaceutical‑grade amino acids, minerals and organic intermediates (e.g., AKG, L‑citrulline, calcium malate, DL‑malate), has maintained a steady flow of 3‑5 shipments per month since 2023, averaging 20‑80 k kg per run and typically utilizing 5‑10 TEU. Core trade corridors are Chinese ports (Xingang, Tianjin, Qingdao, Ningpo, Shanghai, Pusan) to major U.S. West Coast gateways (Los Angeles, Long Beach) with occasional deliveries to New York/Newark and Tacoma, reflecting predictable routing and high port‑of‑loading consistency. Top buyers include HARD EIGHT NUTRITION LLC, JSW ENTERPRISE LLC, FULLER ENTERPRISE USA INC and HARWARS BIOPHARMA INC, indicating strong demand from nutraceutical and biotech segments; repeat orders and concentrated weight shares (up to 40 % from a single buyer) signal reliability and a focused product portfolio. Customs brokers benefit from the company’s consistent HS‑code usage (071331, 120924, 293624, 280512) and repeat port pairings, which streamline documentation, reduce classification disputes and support efficient clearance. Overall, JING JING PHARMACEUTICAL offers buyers a dependable source of high‑purity pharma ingredients with predictable logistics, while providing brokers a low‑risk, well‑documented clearance profile.